Abstract
EBV is associated to the development of several malignancies of lymphoid and epithelial origin, including Burkitts Lymphoma, post-transplant lymphoproliferative disorders, Hodgkins disease, AIDS-associated lymphomas, NK/T cell lymphoma and Nasopharyngeal carcinoma. EBV genes play an essential role in the development of the malignant phenotype and therefore molecules interfering with the function of these genes may represent an essential tool to treat EBV-associated malignancies. Several strategies to inhibit virus-induced tumorigenesis have been developed including antiviral and antitumor molecules, gene therapy approaches, interference with epigenetic regulatory mechanisms, adoptive and active immunotherapeutic protocols. While gene therapy and epigenetic approaches gave inconsistent results, immunological therapies using ex vivo expanded autologous and allogenic cells specific for EBV have obtained promising results. The major challenge is now to improve the current knowledge on virus replication strategies and on the characteristics of protective immune response that may result in more effective therapeutic protocols.
Keywords: EBV, Burkitt's Lymphoma, Hodgkin's disease, AIDS-associated lymphomas, NK/T cell lymphoma, Nasopharyngeal carcinoma, tumorigenesis, antitumor molecules, allogenic cells, EPSTEIN BARR VIRUS
Current Cancer Drug Targets
Title: Novel Virally Targeted Therapies of EBV-Associated Tumors
Volume: 8 Issue: 7
Author(s): Paolo De Paoli
Affiliation:
Keywords: EBV, Burkitt's Lymphoma, Hodgkin's disease, AIDS-associated lymphomas, NK/T cell lymphoma, Nasopharyngeal carcinoma, tumorigenesis, antitumor molecules, allogenic cells, EPSTEIN BARR VIRUS
Abstract: EBV is associated to the development of several malignancies of lymphoid and epithelial origin, including Burkitts Lymphoma, post-transplant lymphoproliferative disorders, Hodgkins disease, AIDS-associated lymphomas, NK/T cell lymphoma and Nasopharyngeal carcinoma. EBV genes play an essential role in the development of the malignant phenotype and therefore molecules interfering with the function of these genes may represent an essential tool to treat EBV-associated malignancies. Several strategies to inhibit virus-induced tumorigenesis have been developed including antiviral and antitumor molecules, gene therapy approaches, interference with epigenetic regulatory mechanisms, adoptive and active immunotherapeutic protocols. While gene therapy and epigenetic approaches gave inconsistent results, immunological therapies using ex vivo expanded autologous and allogenic cells specific for EBV have obtained promising results. The major challenge is now to improve the current knowledge on virus replication strategies and on the characteristics of protective immune response that may result in more effective therapeutic protocols.
Export Options
About this article
Cite this article as:
De Paoli Paolo, Novel Virally Targeted Therapies of EBV-Associated Tumors, Current Cancer Drug Targets 2008; 8 (7) . https://dx.doi.org/10.2174/156800908786241069
DOI https://dx.doi.org/10.2174/156800908786241069 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential of Plant-Derived Natural Products in the Treatment of Leukemia and Lymphoma
Current Drug Targets Radiation-Induced Extracranial Carotid Stenosis
Vascular Disease Prevention (Discontinued) Hormone Responsive Breast Cancer and BRCA1 Mutation: Mechanism, Regulation and Iron-mediated Effects
Current Pharmaceutical Biotechnology Epidemiology and Prevention of Viral Infections in Patients with Hematologic Malignancies
Infectious Disorders - Drug Targets Diffuse Large B-Cell Lymphoma with Involvement of the Chest Wall
Current Respiratory Medicine Reviews Serum Proteomics in the Diagnosis and Treatment of Haematological Malignancies
Current Proteomics Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Current Pharmaceutical Biotechnology Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies
Current Pharmaceutical Design Epstein-Barr Virus Infection and its Pathogenetic Roles for Human Diseases
Current Pediatric Reviews Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Deep Inspiration Breath-hold (DIBH) Technique to Reduce Cardiac Radiation Dose in the Management of Breast Cancer
Current Cancer Therapy Reviews Late Effects in Survivors of Childhood CNS Tumors: Review of Results From the Two Largest Survivorship Cooperative Groups
Current Cancer Therapy Reviews A New Antitumor Agent, (3-chloro-7-methoxyfuro[2,3-b]-quinolin-4-yl)-(4-methoxyphenyl) amine, Loaded in Solid Lipid Nanoparticles: Characterization and Pharmacokinetics
Current Nanoscience Recent Advances in T Cell Adoptive Immunotherapy of Cancer
Current Cancer Therapy Reviews The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology
Current Medicinal Chemistry Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Current Drug Delivery